Valuation Charles River Laboratories International, Inc.

Stocks

Market Closed - NYSE 04:00:02 2026-10-23 pm EDT			5-day change	1st Jan Change
345.37 ^USD	+1.68%		+15.07%	+73.14%

Oct. 22	Labcorp, Charles River Laboratories and U.S. Food and Drug Administration Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential	CI
Oct. 14	JPMorgan Adjusts Price Target on Charles River Laboratories International to $345 From $310	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	18,941	11,138	12,252	9,520	10,023	16,488	-	-
Change	-	-41.2%	10%	-22.3%	5.29%	64.49%	-	-
Enterprise Value (EV) ¹	21,366	13,616	14,622	11,565	11,946	18,592	18,212	17,782
Change	-	-36.28%	7.39%	-20.91%	3.29%	55.64%	-2.04%	-2.36%
P/E	49.4x	23.1x	25.9x	931x	-70x	85.7x	36.9x	32.7x
PBR	7.45x	3.75x	3.41x	2.75x	3.17x	5.3x	4.65x	4.07x
PEG	-	0.9x	-9.44x	-9.5x	0x	-0x	0x	2.5x
Capitalization / Revenue	5.35x	2.8x	2.97x	2.35x	2.5x	4.21x	4.11x	3.88x
EV / Revenue	6.04x	3.42x	3.54x	2.86x	2.98x	4.75x	4.53x	4.18x
EV / EBITDA	24.3x	13.7x	14.4x	11.6x	12.3x	18.2x	16.4x	15x
EV / EBIT	28.8x	16.3x	17.4x	14.3x	15x	22.6x	19.8x	17.3x
EV / FCF	40.2x	46.2x	40x	23.1x	23x	61.8x	35.5x	35.2x
FCF Yield	2.49%	2.17%	2.5%	4.34%	4.34%	1.62%	2.82%	2.84%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	7.6	9.48	9.22	0.2	-2.91	4.03	9.358	10.57
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	3,540	3,976	4,129	4,050	4,015	3,917	4,016	4,251
EBITDA ¹	879.5	990.9	1,013	996.1	971.5	1,021	1,108	1,187
EBIT ¹	742.1	834	838.8	805.9	793.9	822.5	922.1	1,026
Net income ¹	391	486.2	474.6	10.3	-144.3	187	436.8	488.7
Net Debt ¹	2,425	2,477	2,370	2,046	1,923	2,105	1,725	1,294
Reference price ²	375.34	218.92	238.84	186.16	203.66	345.37	345.37	345.37
Nbr of stocks (in thousands)	50,464	50,879	51,297	51,136	49,215	47,739	-	-
Announcement Date	2/16/22	2/22/23	2/14/24	2/19/25	2/18/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	85.69x	4.75x	18.22x	-.--%	16.49B
WUXI APPTEC CO., LTD.	18.83x	6.63x	13.18x	1.58%	64.69B
ARGENX SE	30.16x	7.93x	26.43x	0.05%	54.78B
LONZA GROUP AG	36.79x	6.53x	19.51x	0.88%	53.49B
IQVIA HOLDINGS INC.	35.59x	3.45x	14.87x	-.--%	45.98B
BEONE MEDICINES AG	49.71x	5.74x	31.52x	-.--%	42.94B
REVOLUTION MEDICINES, INC.	-19.41x	187.75x	-20.66x	-.--%	40.08B
CELLTRION, INC.	28.93x	8.21x	21.27x	0.37%	33.52B
GENMAB A/S	32.66x	5.97x	20.09x	-.--%	23.67B
WUXI BIOLOGICS (CAYMAN) INC.	27.67x	5.83x	15.12x	-.--%	23.97B
Average	32.66x	24.28x	15.96x	0.29%	39.96B
Weighted average by Cap.	29.15x	24.47x	16.03x	0.41%